Alex Azar, the president’s nominee to head the Dept. of Health & Human Services, has nearly a decade of experience in the pharmaceutical industry – and that experience is either predictive of his inability to act on lowering drug prices or will serve him well as HHS chief, depending on who you ask.
At Azar’s Senate confirmation hearing yesterday, Republicans argued that his time at insulin-maker Eli Lilly (NYSE:LLY) gives him insight into how HHS policies ultimately affect industry. Democrats pushed back, probing Azar about the drug-price increases that took place at Eli Lilly while he was working there.
Get the full story at our sister site, Drug Delivery Business News.
The post At confirmation hearing for Trump’s HHS nominee, drug pricing takes center-stage appeared first on MassDevice.